10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures

IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures

Core Regulatory Standard: Under ICH E6(R3) Annex 1 section 2.10 (Investigational Product(s)) and 21 CFR 312.62 (Investigator Recordkeeping and Product Control), the Principal Investigator bears ultimate legal responsibility for maintaining complete, accurate, and real-time accountability for all investigational products delivered to the site. Failure to account for every single unit of investigational drug or device represents one of the most frequent citations on FDA Form 483 inspection observations and major audit findings.

---

1. Physical Storage Security & Access Control

Investigational products must be segregated from commercial pharmacy inventory and stored in a secure environment that prevents diversion, contamination, and unauthorized access.

┌───────────────────────────────────────────────────────────────────────────┐
│                     IP STORAGE SECURITY REQUIREMENTS                      │
├───────────────────────────────────────────────────────────────────────────┤
│  1. DOUBLE-LOCK SECURITY: Stored in a locked dedicated room, locked       │
│     cabinet, or locked refrigerator inside an access-controlled area.     │
│  2. RESTRICTED ACCESS: Physical keys or electronic keycards are issued    │
│     ONLY to individuals explicitly delegated IP management duties on the  │
│     Delegation of Authority Log (DOAL) (e.g., Research Pharmacist, CRC).  │
│  3. PHYSICAL SEGREGATION: IP must never be mixed with routine commercial  │
│     hospital stock or products from other clinical protocols.             │
│  4. CONTROLLED SUBSTANCES (DEA SCHEDULE II-V): Investigational narcotics  │
│     or controlled substances must be stored in a permanently bolted,      │
│     substantially constructed steel safe meeting 21 CFR Part 1301.72 rules.│
└───────────────────────────────────────────────────────────────────────────┘

Segregation of Unblinded Materials

In double-blind studies where the site pharmacy prepares open-label or unblinded formulations (e.g., active drug ampoules vs. normal saline vials), unblinded stock and unblinded preparation binders must be stored in a separate, locked compartment accessible only to the unblinded research pharmacist. Blinded study coordinators and investigators must never have access to this area.

---

2. The Investigational Drug Accountability Log (DAR / IPAL)

The Drug Accountability Record (DAR)—also called the Investigational Product Accountability Log (IPAL)—is the primary regulatory document that tracks the full lifecycle of every dosage unit delivered to the trial site.

┌───────────────────────────────────────────────────────────────────────────┐
│                    THE COMPLETE IP ACCOUNTABILITY LIFECYCLE               │
├───────────────────────────────────────────────────────────────────────────┤
│  [CENTRAL DEPOT] ──► [SITE RECEIPT] ──► [STORAGE INVENTORY]               │
│                             │                                             │
│                             ▼                                             │
│                    [DISPENSED TO SUBJECT]                                 │
│                             │                                             │
│                             ▼                                             │
│                   [RETURNED BY SUBJECT]                                   │
│                             │                                             │
│                             ▼                                             │
│            [100% FINAL MONITOR RECONCILIATION]                            │
│                             │                                             │
│              ┌──────────────┴──────────────┐                              │
│              ▼                             ▼                              │
│    [RETURN TO SPONSOR]           [ON-SITE DESTRUCTION]                    │
│    (Signed Packing Slip)         (Certificate of Destruction)             │
└───────────────────────────────────────────────────────────────────────────┘

Master vs. Subject-Specific Accountability Logs

1. Master Drug Accountability Log: Tracks the overall inventory balance of all shipments received at the site, total units dispensed across all subjects, units damaged or wasted, and current balance on hand in the pharmacy vault.
2. Subject-Specific Dispensing Log: Maintained inside each participant's study binder, recording every kit number dispensed to and returned by that individual subject across all scheduled protocol visits.

Mandatory Regulatory Data Fields on the IPAL (21 CFR 312.62 & ICH 4.6.3)

ALCOAC Principle in IP Logging: IPAL entries must be made in real-time at the exact moment of receipt, dispensing, or return. Back-dating, delayed batch-logging at the end of the week, or erasing pencil notes violates ALCOAC (Attributable, Legible, Contemporaneous, Original, Accurate, Complete) standards.

---

3. Dispensing Procedures & Dose Modifications

Dispensing investigational medication is a highly controlled clinical workflow requiring multiple cross-checks prior to handing the product to the participant.

┌───────────────────────────────────────────────────────────────────────────┐
│                      THE 6-POINT DISPENSING CHECKLIST                     │
├───────────────────────────────────────────────────────────────────────────┤
│  1. VERIFY INVESTIGATOR PRESCRIPTION: Confirm signed prescription/order   │
│     from an authorized Investigator/Sub-Investigator listed on Form 1572. │
│  2. VERIFY ELIGIBILITY & VISIT WINDOW: Confirm subject has completed all  │
│     required safety labs (e.g., liver enzymes, pregnancy test) and is     │
│     within the protocol-defined visit scheduling window.                  │
│  3. IRT / RTSM ASSIGNMENT: Query interactive web system to receive the    │
│     exact kit number assigned dynamically to that specific Subject ID.    │
│  4. TWO-PERSON PHYSICAL VERIFICATION: Cross-check kit ID on the physical  │
│     box against the IRT allocation screen and the prescription.           │
│  5. AFFIX PATIENT-SPECIFIC LABEL: Add Subject ID, visit number, date, and │
│     detailed dosing instructions per local pharmacy regulations.          │
│  6. PATIENT COUNSELING: Verbally review dosing instructions, missed dose  │
│     rules, dietary restrictions, storage conditions, and the requirement  │
│     to return all unused medication and empty bottles at the next visit.  │
└───────────────────────────────────────────────────────────────────────────┘

Dose Titrations, Reductions, and Interruptions

When a protocol specifies dose modifications (e.g., reducing from 100 mg daily to 50 mg daily due to Grade 2 thrombocytopenia):

• The PI must write a formal dose modification order in the medical source records.
• The IRT system must be updated with the dose level adjustment.
• The exact kit containing the reduced strength must be dispensed, and the dose modification documented on the IPAL with a corresponding medical explanatory note.

---

4. Subject Compliance Verification & Pill Count Calculations

At every protocol return visit, research staff must perform physical medication reconciliation and calculate the subject's therapeutic compliance rate.

The Standard Medication Adherence Formula

\text{Medication Compliance (\%)} = \left( \frac{\text{Quantity Dispensed} - \text{Quantity Returned}}{\text{Quantity Expected to be Consumed}} \right) \times 100\%$$$$\text{Where: Quantity Expected} = \text{Prescribed Doses per Day} \times \text{Number of Days Between Visits}

Practical Mathematical Compliance Calculation

┌───────────────────────────────────────────────────────────────────────────┐
│                     SAMPLE ADHERENCE CALCULATION CASE                     │
├───────────────────────────────────────────────────────────────────────────┤
│  • Protocol Dosing: 2 capsules orally once daily                          │
│  • Visit Interval: 28 days between Visit 2 (Dispense) and Visit 3 (Return)│
│  • Quantity Dispensed at Visit 2: 60 capsules (30-day supply)             │
│  • Quantity Returned at Visit 3: 8 capsules                               │
│                                                                           │
│  CALCULATION:                                                             │
│  1. Actual Consumed = 60 dispensed - 8 returned = 52 capsules consumed    │
│  2. Expected Consumed = 2 capsules/day * 28 days = 56 capsules expected   │
│  3. Compliance Rate = (52 / 56) * 100% = 92.86%                           │
│                                                                           │
│  EVALUATION: Compliance is 92.9% (Falls within acceptable 80% - 120% range)│
└───────────────────────────────────────────────────────────────────────────┘

Managing Compliance Outliers (<80% or >120%)

• Under-Compliance (<80%): Subject took fewer doses than prescribed (e.g., missed doses due to nausea or forgetfulness). Staff must retrain the subject, explore adherence barriers, document reasons in source records, and evaluate whether protocol non-compliance criteria are met.
• Over-Compliance (>120%): Subject took more medication than prescribed (e.g., doubling doses after forgetting). The PI must immediately evaluate the subject for toxicity, report potential overdose if required by the protocol, and re-educate the participant.
• Lost or Discarded Units: If a participant loses a blister strip or throws away empty bottles, staff must document the subject's verbal accounting in source records and mark the units as 'Lost by Subject' on the IPAL (never assume or fabricate returned counts).

---

5. IP Return, Final Reconciliation & Destruction Procedures

At the conclusion of a clinical trial or following protocol-defined intervals, all investigational products must undergo 100% final mathematical reconciliation.

┌───────────────────────────────────────────────────────────────────────────┐
│                  100% FINAL IP RECONCILIATION EQUATION                    │
├───────────────────────────────────────────────────────────────────────────┤
│  TOTAL UNITS RECEIVED                                                     │
│     EQUALS (=)                                                            │
│  TOTAL UNITS DISPENSED (Consumed + Returned)                              │
│     PLUS (+)                                                              │
│  TOTAL UNUSED UNITS REMAINING IN INVENTORY                                │
│     PLUS (+)                                                              │
│  TOTAL UNITS DAMAGED, LOST, OR WASTED (Documented)                        │
└───────────────────────────────────────────────────────────────────────────┘

Disposition Pathway: Return to Depot vs. On-Site Destruction

Once the monitor (CRA) completes physical source data verification and counts all unused and returned IP, the final disposition occurs via one of two authorized pathways:

                             ┌──────────────────────────────────┐
                             │  FINAL IP RECONCILIATION BY CRA  │
                             └─────────────────┬────────────────┘
                                               │
                     ┌─────────────────────────┴─────────────────────────┐
                     ▼                                                   ▼
       ┌───────────────────────────┐                       ┌───────────────────────────┐
       │  PATHWAY A: RETURN DEPOT  │                       │  PATHWAY B: DESTRUCTION   │
       │ • Pack returned & unused  │                       │ • Prior written sponsor OK│
       │ • Complete return manifest│                       │ • Institutional biohazard │
       │ • Courier chain-of-custody│                       │ • 2 witness signatures    │
       │ • Depot receives & signs  │                       │ • Cert of Destruction     │
       └───────────────────────────┘                       └───────────────────────────┘

Mandatory Requirements for On-Site Destruction:

1. Prior Written Sponsor Authorization: Sites must never destroy investigational drug on site based on verbal discussions. Formal written approval (e.g., an executed Sponsor IP Destruction Authorization Letter) is legally mandatory.
2. Compliance with Local Environmental & Hazardous Waste Laws: Cytotoxic agents, biologics, or chemical toxins must be incinerated or processed via licensed biohazard waste vendors in compliance with EPA/local environmental regulations.
3. Controlled Substances (DEA Rules): Destruction of Schedule II-V investigational narcotics must comply with 21 CFR Part 1317 and DEA regulations, requiring DEA Form 41 (Registrant Record of Controlled Substances Destroyed) and submission to the DEA Field Division.
4. Certificate of Destruction: A comprehensive legal document executed immediately upon destruction, detailing:
   • Protocol number and site number
   • Product name, dosage form, and strength
   • Lot/batch numbers and kit serial numbers destroyed
   • Exact quantity destroyed (in units/tablets/vials)
   • Method of destruction (e.g., high-temperature incineration, chemical denaturation)
   • Date, time, and physical location of destruction
   • Printed names and signatures of at least two qualified witnesses (e.g., the Research Pharmacist and the Principal Investigator or Quality Manager).

---

6. Realistic Clinical Scenario & ACRP-CP Case Analysis

Clinical Scenario: A Clinical Research Associate (CRA) is conducting a close-out monitoring visit at an investigational site for a completed Phase III diabetes study. During final IP reconciliation, the CRA identifies the following discrepancies between the pharmacy inventory and the Master IPAL:

1. The Master IPAL indicates that 100 kits of GLUC-10 were received. 80 kits were dispensed to subjects, and 20 unused kits remain in the pharmacy vault. However, a physical count of the vault reveals only 18 unused kits (2 kits missing).
2. For Subject #105 at Visit 4, the coordinator documented that the subject returned 0 tablets out of 60 dispensed. The coordinator wrote in the source notes: "Subject states he threw the empty bottle into the municipal recycling bin after taking the last dose."
3. The site pharmacist destroyed 10 expired return kits in the hospital incinerator two weeks prior to the close-out visit without notifying the sponsor, stating that "hospital SOP requires destroying expired drugs immediately."

ACRP-CP Compliance Evaluation & Audit Resolution:

• Finding 1 Resolution (Missing Kits): The discrepancy of 2 missing kits represents an unresolved inventory imbalance. The site must conduct an immediate physical search and audit trail review of all dispensing logs and IRT transactions. If the kits cannot be located, the PI must file a formal Missing IP Incident Report, document the loss on the Master IPAL, execute a root-cause investigation, and submit the report to the sponsor and IRB.
• Finding 2 Resolution (Subject Discarded Bottle): The coordinator correctly recorded the subject's verbal explanation in the source record. On the IPAL, the coordinator must record: "Quantity Returned: 0 (60 tablets consumed per subject interview; empty container discarded by subject)." Staff must never record unreturned containers as returned or alter numbers to make logs balance.
• Finding 3 Resolution (Unauthorized Destruction Violation): The pharmacist's unauthorized destruction of expired study drug is a major GCP non-compliance violation. Site SOPs cannot override GCP requirements for sponsor authorization. The site must issue an urgent deviation notification, obtain an after-the-fact statement from the incineration facility, execute a formal corrective and preventive action (CAPA) plan, and retrain pharmacy staff on sponsor destruction workflows.